US equities |
MU $926.20 ▼-2.83% NVDA $220.66 ▼-3.44% AAPL $342.70 ▲+0.42% AMD $572.74 ▼-5.42% META $736.77 ▼-3.37% TSLA $364.47 ▼-2.87% SPCX $151.93 ▼-2.95% SNDK $1,415.47 ▼-4.51%
FinancialContent

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

0.8471 -0.4129 (-32.77%)
Delayed Quote Updated: 2:25 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Stocks Mixed After Upbeat Consumer Confidence Data ↗
The Dow Jones Industrial Average managed to swing into positive territory this afternoon, though the S&P 500 Index and Nasdaq Composite Index are still sitting in the red. 
Via Talk Markets
News headline image
Where Biomea Fusion Stands With Analysts ↗
 
Via Benzinga
News headline image
Dow Rises 50 Points; Harmony Biosciences Shares Plunge ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 50 points on Tuesday. The Dow traded up 0.16% to 32,484.24 while the NASDAQ fell 0.75% to 11,681.12. The S&P 500, also... 
Via Benzinga
News headline image
Why Shares of Biomea Fusion Jumped This Week ↗
The company launched its second trial this year for its lead therapy. 
Via The Motley Fool
Analyst Expectations for Biomea Fusion's Future ↗
 
Via Benzinga
News headline image
Biomea Fusion (NASDAQ: BMEA) Reports Positive Initial Findings From the COVALENT-111 Phase II Study of BMF-219 for the Treatment of Type 2 Diabetes
Biomea Fusion, Inc. (NASDAQ: BMEA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, discovery and 
Via Spotlight Growth
News headline image
What's Driving Biomea Fusion Shares Higher Today? ↗
Biomea Fusion Inc (NASDAQ: BMEA) shares are trading higher Tuesday after the company announced data from the initial cohorts of the ongoing Phase II study of BMF-219 in patients with 
Via Benzinga
News headline image
Nasdaq Down Over 50 Points; US Goods Trade Deficit Widens Slightly ↗
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.01% to 32,436.22 while the NASDAQ fell... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
From Biomea Fusion, Inc.
Via GlobeNewswire
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
News headline image
Biomea Fusion To Participate In Upcoming Investor Events
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 ↗
 
Via Benzinga
News headline image
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
US Stocks Edge Lower; Bank of America Profit Tops Views ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping around 50 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
Via MarketBeat
News headline image
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
BMF-219 Enters the Clinic for KRAS Solid Tumors
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >